HAIC shows effectiveness and tolerance in pMMR/MSS CRLM patients who are refractory to systemic therapy. However, the additive value of targeted therapy for HAIC in these patients needs to be further investigated.
Li et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: